New hope for esophageal cancer patients: trial tests powerful Pre-Surgery combo
NCT ID NCT07385001
Summary
This study is testing a new combination of drugs given before surgery for people with a type of esophageal cancer that can be surgically removed but is locally advanced. The goal is to see if adding a newer immunotherapy drug (AK112) to standard chemotherapy drugs helps shrink the tumor more effectively and improves long-term results. The trial will first find the safest dose and then see how well the combination works in about 45 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospitial
RECRUITINGXi'an, Shannxi, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.